Supernus reports Phase 2a data for SPN-820, stock climbs 6% [Seeking Alpha]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Seeking Alpha
from a Phase 2a study of its drug SPN-820 for the treatment of major depressive disorder in adults. Supernus ( SUPN ) said it expects to complete enrollment in a Phase 2b study of SPN-820 in adults with treatment-resistant depression in November, with topline results expected in the first half of 2025, according to a statement. More on Supernus Pharmaceuticals Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript Supernus cut to Neutral at Piper Sandler on Qelbree growth trajectory Supernus Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook Seeking Alpha's Quant Rating on Supernus Pharmaceuticals Recommended For You Comments More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.MarketBeat
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewswire
- Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceGlobeNewswire
- Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
SUPN
Earnings
- 11/4/24 - Beat
SUPN
Sec Filings
- 12/30/24 - Form 4
- 12/30/24 - Form 4
- 12/26/24 - Form 4
- SUPN's page on the SEC website